Have a feature idea you'd love to see implemented?
Let us know!
DSGN Design Therapeutics Inc
Price (delayed)
$5.57
Market cap
$315.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.85
Enterprise value
$286.8M
Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on
Highlights
The EPS rose by 35% year-on-year and by 6% since the previous quarter
DSGN's net income is up by 34% YoY and by 5% QoQ
The quick ratio has grown by 46% YoY but it has contracted by 16% from the previous quarter
Design Therapeutics's equity has decreased by 11% YoY and by 3.4% QoQ
Key stats
What are the main financial stats of DSGN
Market
Valuations
Earnings
Shares outstanding
56.62M
Market cap
$315.38M
Enterprise value
$286.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$47.78M
EBITDA
-$47.18M
Free cash flow
-$46.41M
Per share
Balance sheet
Liquidity
EPS
-$0.85
Free cash flow per share
-$0.82
Book value per share
$4.46
Revenue per share
$0
TBVPS
$4.62
Total assets
$261.63M
Total liabilities
$9.18M
Debt
$1.74M
Equity
$252.45M
Working capital
$249.81M
Debt to equity
0.01
Current ratio
34.61
Quick ratio
34.19
Net debt/EBITDA
0.61
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-17.4%
Return on equity
-18%
Return on invested capital
-20.1%
Return on capital employed
-18.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DSGN stock price
How has the Design Therapeutics stock price performed over time
Intraday
1.64%
1 week
-7.48%
1 month
-0.54%
1 year
154.34%
YTD
110.19%
QTD
3.53%
Financial performance
How have Design Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$60.81M
Net income
-$47.78M
Gross margin
N/A
Net margin
N/A
DSGN's net income is up by 34% YoY and by 5% QoQ
DSGN's operating income is up by 26% year-on-year and by 4.1% since the previous quarter
Growth
What is Design Therapeutics's growth rate over time
Valuation
What is Design Therapeutics stock price valuation
P/E
N/A
P/B
1.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 35% year-on-year and by 6% since the previous quarter
DSGN's P/B is 56% above its last 4 quarters average of 0.8
Design Therapeutics's equity has decreased by 11% YoY and by 3.4% QoQ
Efficiency
How efficient is Design Therapeutics business performance
DSGN's ROE is up by 24% YoY and by 2.7% QoQ
Design Therapeutics's ROA has increased by 23% YoY and by 2.2% from the previous quarter
The company's return on invested capital rose by 21% YoY
Dividends
What is DSGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DSGN.
Financial health
How did Design Therapeutics financials performed over time
DSGN's current ratio is up by 46% year-on-year but it is down by 16% since the previous quarter
The quick ratio has grown by 46% YoY but it has contracted by 16% from the previous quarter
DSGN's debt is 99% smaller than its equity
DSGN's debt is down by 31% year-on-year and by 10% since the previous quarter
Design Therapeutics's equity has decreased by 11% YoY and by 3.4% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.